drugset / Trial / NCT05145621

Oral Bio-equivalence Study

NCT05145621

Phase 1 Completed 26 enrolled Alembic Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

Title of Study: An Open-Label, Balanced, Randomized, 2-Treatment, 2-Sequence, 2-Period, Single Dose, Crossover Oral Bioequivalence Study of Two Formulations of Fingolimod Capsules (3 x 0.5 mg) in Healthy Adult Human Subjects Under Fasting Conditions. Objective: The objective of this study is to compare the oral bioavailability and characterize the pharmacokinetic profile of the test formulation relative to that of reference formulation in healthy, adult, human subjects under fasting conditions and to assess the bioequivalence.

Timeline

Start
2015-10-29
Primary completion
2016-01-15
Completion
2016-01-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fingolimod Small molecule 1.5 mg Oral

Indications

No indication recorded.